Stem Cell Transplant and Cellular Therapy- Autologous

- **Multiple Myeloma**
  - IRB# 17699: Phase III 2-part randomized study comparing G-CSF + BL-8040 with G-CSF + placebo for mobilization before autologous stem cell transplant
  - IRB# 9398: Phase III comparing lenalidamide, bortezomib, dexamethasone (RVD) to High Dose treatment with peripheral stem cell transplant
- **Previously Untreated**
- **Mantle Cell Lymphoma**
- **AML and MDS**
  - IRB# 15993: Phase 1 relapsed or refractory myeloid neoplasms. Must express HLA-A2.01 and PRAME
- **DLBCL**
  - IRB# 16830: Alliance/CTN Ibrutinib for ABC subtype
- **CAR-T Treatment**
  - IRB# 18449: A Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adults with High-Risk, Transplant-Eligible, Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM)
  - IRB# 18600: Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed or Refractory Multiple Myeloma

[Key]
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

5/29/2018